G66E (p.Gly66Glu) variant of NAT2 (Arylamine N-acetyltransferase 2)
G66E (p.Gly66Glu) in NAT2 (Arylamine N-acetyltransferase 2) is a missense change. Clinical records from UniProt describe it as variant assessed as somatic; moderate impact. The available variant effect predictions contribute to a CATVariant prioritization score of 0.58 / 1. The record also includes population frequency data and structural context.
G66E (p.Gly66Glu) variant details
- p.Gly66Glu
- NCI-TCGA Cosmic COSV5406
- Variant assessed as somatic; moderate impact.
- Missense
- Variant Prioritization Score for Impact Estimate 0.578
- REVEL 0.51
- CADD 25.00
- PolyPhen-2 1.00
- SIFT 0.00
- UniProt: Variant assessed as somatic; moderate impact.
- Most common in the Non-Finnish European population (allele frequency 9e-07)
- Structural context available